Scrotal mass differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 19: Line 19:
| colspan="7" | Germ Cell Tumors
| colspan="7" | Germ Cell Tumors
|-
|-
| [[Seminoma]]
|'''[[Seminoma]]'''
|
|
*Most common
*Most common
Line 40: Line 40:
*Stains positively for ALP, c-KIT, CD30, EMA, and glycogen
*Stains positively for ALP, c-KIT, CD30, EMA, and glycogen
|-
|-
| Embryonal cell carcinoma
|'''Embryonal cell carcinoma'''
|  
|  
*Young adults
*Young adults
Line 62: Line 62:
*May stain positively for AFP, when mixed
*May stain positively for AFP, when mixed
|-
|-
| [[Yolk sac tumor]]
|'''[[Yolk sac tumor]]'''
|  
|  
* Most common testicular cancer in children less than 3 years of age
* Most common testicular cancer in children less than 3 years of age
Line 81: Line 81:
*Stains positively for AFP, alpha-1-antitrypsin, PAS diastase
*Stains positively for AFP, alpha-1-antitrypsin, PAS diastase
|-
|-
| [[Teratoma]]
|'''[[Teratoma]]'''
|  
|  
*Bimodal distribution of age (infants and middle aged adults)
*Bimodal distribution of age (infants and middle aged adults)

Revision as of 15:51, 16 March 2016

Scrotal Mass Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Scrotal Mass from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Studies

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Scrotal mass differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Scrotal mass differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Scrotal mass differential diagnosis

CDC on Scrotal mass differential diagnosis

Scrotal mass differential diagnosis in the news

Blogs on Scrotal mass differential diagnosis

Directions to Hospitals Treating bone or soft tissue mass

Risk calculators and risk factors for Scrotal mass differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

Overview

Differential Diagnosis

The table below summarizes the findings that differentiates scrotal mass according to the clinical features, laboratory findings, imaging features, histological features, and genetic studies.

Disease Name History and Symptoms Physical Examination Lab Findings Imaging Findings Gross and Histologic Findings Genetic Studies / Immunohistochemistry
Germ Cell Tumors
Seminoma
  • Most common
  • 30-50 year-old with painless unilateral testicular mass or mild discomfort
  • Palpable, nontender unilateral testicular mass
  • Usually homogeneous enlargement
  • Elevated serum placental ALP (PALP)
  • Hypoechogenic intratesticular well-defined mass on ultrasound with internal blood flow on Doppler ultrasound
  • Cysts and calcificications are uncommon
  • Hypointense lesion with inhomogeneous enhancement on MRI
  • Homogeneous when small and heterogeneous when large
  • Grey-white homogeneous mass with a lobular appearance
  • Fried egg appearance on histopathology (large cells and clear cytoplasm)
  • Prominent lymphocytic infiltration and less commonly, granulomatous formation
  • Stains positively for ALP, c-KIT, CD30, EMA, and glycogen
Embryonal cell carcinoma
  • Young adults
  • Painful testicular mass
  • Manifests with early mestastasis (bone, lung, CNS)
  • Often unremarkable (small primary tumor)
  • Elevated serum hCG
  • Elevated serum AFP, when mixed
  • Variable echogenicity (usually hypoechoic on ultrasound)
  • No differentiating features on imaging
  • Commonly invade the surrounding structures (tunica albuginea)
  • Irregular calcifications
  • Pale-grey mass with areas of hemorrhagic and necrosis
  • Often mixed histopathological features (solid, papillary, tubular, pseudoglandular)
  • Stains positively for CD30 and hCG stain
  • May stain positively for AFP, when mixed
Yolk sac tumor
  • Most common testicular cancer in children less than 3 years of age
  • Rapidly growing unilateral mass in an infant or a young child
  • Palpable, nontender unilateral testicular mass
  • Usually heterogeneous enlargement
  • Elevated serum AFP
  • Diffuse enlargement of the testis with a heterogeneous appearance on ultrasound
  • Areas of hemorrhage and necrosis on MRI
  • Yellow, mucinous, non-encapsulated, heterogeneous mass with areas of necrosis and hemorrhage
  • Patterns that resemble embryonal structures (yolk sac, allantois) with reticular, papillary, or elongated forms
  • Schiller-Duval bodies (perivascular structures)
  • Stains positively for AFP, alpha-1-antitrypsin, PAS diastase
Teratoma
  • Bimodal distribution of age (infants and middle aged adults)
  • Painless tumor
  • History of congenital disease (Down syndrome, klinefelter, spina bifida)
  • Palpable, nontender unilateral testicular mass
  • Usually heterogeneous enlargement
  • Elevated serum hCG
  • Elevated serum AFP
  • Heterogeneous, cystic appearance with mucinous or sebaceous depositions
  • Variable echogenicity on ultrasound
  • Calcifications usually irregular
  • Large, heterogeneous appearance with solid, cystic, mucoid, and/or cartilageanous components
  • Presence of at least 2 germ layers
  • Chromosome 12p mutations
  • Stains positively for cytokeratin. hCG, and AFP
B
C
D

References

Template:WS Template:WH